Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
Just three months since the US presidential inauguration, and still more developments affecting the future of HIV prevention, global health leadership, and pandemic preparedness. From African women leaders demanding action to save HIV prevention, to escalating US foreign aid cuts and the fragile progress of WHO’s Pandemic Agreement, this issue break down what advocates need to know now.
Blog Post
With the collapse in support from the US Presidential administration in global health, data sources tracking the HIV response have been lost, from HIV incidence and prevalence to PrEP uptake and disparities among key populations and regions of the world.
Blog Post
This week brought major developments for global health: new tariffs on pharmaceuticals are pending, a court blocks the cap on NIH indirect costs, and worries a leadership vacuum at the CDC is a cause for yet more concern. Amid the chaos, advocates rallied—defending PEPFAR’s legacy in Congress and launching a national Black-centered, Black-led HIV research agenda.
showing 1-10 of 1085
Just three months since the US presidential inauguration, and still more developments affecting the future of HIV prevention, global health leadership, and pandemic preparedness. From African women leaders demanding action to save HIV prevention, to escalating US foreign aid cuts and the fragile progress of WHO’s Pandemic Agreement, this issue break down what advocates need to know now.
With the collapse in support from the US Presidential administration in global health, data sources tracking the HIV response have been lost, from HIV incidence and prevalence to PrEP uptake and disparities among key populations and regions of the world.
This week brought major developments for global health: new tariffs on pharmaceuticals are pending, a court blocks the cap on NIH indirect costs, and worries a leadership vacuum at the CDC is a cause for yet more concern. Amid the chaos, advocates rallied—defending PEPFAR’s legacy in Congress and launching a national Black-centered, Black-led HIV research agenda.
Prevention Option:
Just two months ago, AVAC led other organizations to sue the US government including the President, the US State Department and USAID, seeking emergency relief from an Executive Order that inhumanely froze all funding for foreign assistance. This case may well help to determine the future of foreign assistance, executive overreach, and the role of evidence, facts, and values in US policy.
Prevention Option:
This week’s issue covers drastic cuts across the US Department of Health and Human Services (HHS), where a dramatic 20% downsizing effort is underway. The ripple effects are vast—gutting HIV prevention, infectious disease research, and vaccine development, while threatening the stability and viability of the workforce that sustains US public health and biomedical research.
AVAC condemns the US administration’s ongoing reduction in force of the US Department of Health and Human Services, which oversees 13 agencies, including the Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health.
Prevention Option:
This week we’ve seen plans to terminate thousands more USAID awards and completely overhaul the US Department of Health and Human Services, which oversees the National Institutes of Health, the CDC and the FDA. This comes as US funding for vital scientific research in South Africa faces new threats and the future of PEPFAR remains uncertain, with its reauthorization expiring this week amid shifting priorities and budget cuts.
The promise of HIV prevention is just as real as it was before the new administration took office. Only now we must find a new path. To stay on track will require trust, innovation, commitment and investment. Let’s do it.
As the global research community confronts drastic cuts and extraordinary opposition to its work by the US government, the world cannot lose focus on the critical need for high-quality, impactful clinical research.
This newsletter examines the proposed elimination of the US CDC’s HIV prevention program, the uncertain future of foreign assistance globally, lawsuits against the aid freeze, plans to dismantle USAID, while exploring NIH grants in South Africa and the mounting repercussions on communities.
showing 1-10 of 1085
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.